<DOC>
	<DOCNO>NCT01568385</DOCNO>
	<brief_summary>The purpose study study safety efficacy TAK-438 , daily ( QD ) , participant history gastric duodenal ulcer require long-term NSAID therapy investigate .</brief_summary>
	<brief_title>A Unblinded Study TAK-438 ( 20 mg ) Prevention Recurrence Gastric Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug ( NSAID ) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<criteria>1 . Participants , opinion principal investigator subinvestigator , capable understanding detail study comply . 2 . Prior study commencement , participant capable sign date information/consent form . 3 . Participants chronic disease ( rheumatoid arthritis , osteoarthritis , etc . ) require continuous NSAID oral therapy pain control treatment period . 4 . Participants meet either 1 2 accord gastric duodenal endoscopy : Ulcer scar ( define , study , regenerative mucosa , convergence mucosal fold , gastric wall transformation , etc ) confirm endoscopy study drug initiation day ( Visit 2 ) . Ulcer ( mucosal defect 3 mm large white moss ) ulcer scar endoscopically confirm study drug initiation day ( Visit 2 ) . 5 . Outpatient participant ( inpatient examination acceptable ) 6 . Women childbearing potential must agree routinely take appropriate contraceptive measure throughout treatment period , give consent study 4 week final dose 1 . Participants receive treatment another study drug ( include approve drug postmarketing surveillance ) within 84 day prior commencement screen 2 . Participants previously receive TAK438 clinical study treatment 3 . Participants employee institution participate study family member employee , participant dependent relationship employee institution involve conduct study ( e.g. , spouse , parent , child , sibling ) , participant duress give consent 4 . Participants donate 400 mL blood within 90 day prior commencement screen 5 . Participants plan change type , dosage administration NSAID 6 . Participants ulcer ( mucosal defect 3 mm large white moss ) active hemorrhage confirm gastric duodenal endoscopy study drug initiation day ( Visit 2 ) 7 . Participants small intestinal hemorrhage , large intestinal hemorrhage , gastrointestinal hemorrhage unknown cause 8 . Participants history surgery schedule surgery influence gastric acid secretion ( resection upper gastrointestinal tract vagotomy etc ) 9 . Participants history complication ZollingerEllison syndrome , gastric acid hypersecretion disorder 10 . Participants history complication aspirin asthma 11 . Participants history hypersensitivity allergy TAK438 ( include excipients ) NSAIDs 12 . Participants current use illicit drug history drug abuse . and/or alcohol dependence within one year prior commencement screen 13 . Participants require treatment prohibit concomitant drug therapy ( see 7.3 ) 14 . Female participant pregnant lactating ; plan become pregnant donate ova treatment period , give consent 4 week final dose 15 . Participants serious central nervous system disorder , cardiovascular disease , pulmonary disease , hepatic disease , renal disease , metabolic disease , gastrointestinal disorder , urinary disorder , endocrine disease , blood dyscrasia 16 . Participants plan undergo surgery require hospitalization require surgery study period . 17 . Participants history malignancy ( treatment thereof ) within 5 year prior commencement screening ; however , participant completely cure basal cell carcinoma skin carcinoma situ cervix may include study . 18 . Participants acquire immune deficiency syndrome ( AIDS ; include HIV carrier ) hepatitis ( include viral hepatitis carrier [ HBs antigen HCV antibody positive ] ) ; however , participant hepatitis C virus ( HCV ) antigen negative HCVRNA negative may include study . 19 . Participants meet either follow laboratory test value begin screen ( Visit 1 ) Serum creatinine value : high 2 mg/dL Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) : high 2.5 × upper limit normal Total bilirubin : high 2.0 × upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Gastric duodenal ulcer</keyword>
</DOC>